Elk's GDEPT therapy CTL102 has completed Phase I clinical trial work in Europe. The trial included elderly patients suffering from debilitating pain due to loosened hip prostheses but unable to submit to revision surgery due to co-morbidities. Improvement in walking distance and reduction in pain was demonstrated in higher dose patients. No dose limiting toxicity was observed and importantly the repair was completed without the use of general anesthesia. Elk is now preparing for a Phase IIa clinical trial. Please refer to our video for more information.